ClinicalTrials.gg

Program

BI 3810477

A development code.

Its studies are mostly in Idiopathic Pulmonary Fibrosis, led by Boehringer Ingelheim.

Furthest: phase 2, since Nov 3, 20263 company-led studies, 1 open or runningNext primary completion: Jan 27, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Boehringer Ingelheim31 open or runningphase 2since Nov 3, 2026Oct 7, 2024Jan 27, 2028phase 2 · NCT07926321

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 7, 2024First study: phase 1 study in HealthyFirst studyNCT06631430 · 24 enrolled · Belgium
  2. May 15, 2025Phase 1 study in HealthyNCT06984926 · 47 enrolled · Belgium
  3. Nov 3, 2026Phase 2 study in Idiopathic Pulmonary FibrosisPhase 2 reachedNCT07926321 · 70 planned · United States, Belgium, Finland and more

Ahead

  1. Jan 27, 2028Primary completion: phase 2 study in Idiopathic Pulmonary FibrosisNCT07926321

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07926321Idiopathic Pulmonary Fibrosis · United States, Belgium, Finland and more2Not yet recruitingJan 27, 202870
NCT06984926Healthy · Belgium1CompletedMar 9, 202647
NCT06631430Healthy · Belgium1CompletedJun 12, 202524

How it is read

Names in the registry

  • “BI 3810477”, 4 entries

Codes read as this program: BI3810477.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.